Anaptysbio (ANAB) Cash from Financing Activities (2016 - 2026)

Anaptysbio's Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 104.23% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.8 million (down 191.72% YoY) and the FY2025 annual result came in at -$132.6 million, down 204.38% from the prior year.
• Cash from Financing Activities was $1.2 million for Q1 2026 at Anaptysbio, up from -$43.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $71.2 million in Q3 2024 and bottomed at -$50.5 million in Q2 2025.
• A 5-year average of -$1.2 million and a median of -$3.1 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 15263.9% — and 2023, when it plunged 3223.15%.
• Anaptysbio's Cash from Financing Activities stood at $1.9 million in 2022, then tumbled by 364.7% to -$5.2 million in 2023, then jumped by 634.35% to $27.6 million in 2024, then tumbled by 256.47% to -$43.1 million in 2025, then jumped by 102.8% to $1.2 million in 2026.
• Business Quant data shows ANAB's Cash from Financing Activities at $1.2 million in Q1 2026, -$43.1 million in Q4 2025, and -$10.4 million in Q3 2025.